Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Lesions Clear all
Withdrawn No phase listed Observational

ConfirmMDx Assay in Multiparametric MRI (mpMRI) PIRADS Scored Lesions After a Negative MR/US Fusion Biopsy

NCT03597386
View directory record Official record
Conditions
Prostate Disease
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

NCT00413322
View directory record Official record
Conditions
Tumor
Interventions
belinostat, 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Jul 22, 2026, 4:05 PM EDT
Completed No phase listed Observational

Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy

NCT00807820
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Jul 22, 2026, 4:05 PM EDT
Completed No phase listed Observational

The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.

NCT03368989
View directory record Official record
Conditions
Bony Metastases From Castrate Refractory Prostate Cancer
Interventions
Radium-223 dichloride
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 22, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional

AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions

NCT07231627
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bi-parametric MRI-based cascaded deep-learning AI algorithm
Device
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional

Virtual Reality Headset and/or Aromatherapy for Patients Undergoing a Transperineal Prostate Biopsy

NCT06296147
View directory record Official record
Conditions
Prostate Cancer
Interventions
Virtual Reality Headset, Aromatherapy Patch, Standard of Care
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Imaging of Prostate Cancer Using Two-dimensional MR Spectroscopy and Diffusion Tensor Imaging

NCT00611065
View directory record Official record
Conditions
Prostate Lesions
Interventions
magnetic resonance imaging
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years to 80 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jul 22, 2026, 4:05 PM EDT
Terminated Not applicable Interventional Results available

Compassionate Same-Day Evaluation & Delivery of XRT for Bony Metastasis in Hospice Patients

NCT01760941
View directory record Official record
Conditions
Symptomatic Osseous Bone Lesions From Any Malignancy
Interventions
Radiation Therapy, Quality-of-Life Assessment, Survey Administration
Radiation · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Early Phase 1 Interventional Results available

A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy

NCT02115828
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vismodegib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jul 22, 2026, 4:05 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Whole Versus Partial Gland Boost During Prostate SBRT

NCT07574489
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Prostate stereotactic body radiotherapy with whole gland boost, Prostate stereotactic body radiotherapy with DIL boost
Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Male only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Not applicable Interventional Results available

Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions

NCT01657942
View directory record Official record
Conditions
Localized Intermediate Risk Prostate Lesions
Interventions
ExAblate MR Guided Focused Ultrasound
Device
Lead sponsor
InSightec
Industry
Eligibility
50 Years and older · Male only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Jul 22, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional

Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy

NCT06542757
View directory record Official record
Conditions
Prostate Cancer
Interventions
1.5 T Elekta Unity MR-Linac system, Hydrogel rectal spacer (SpaceOAR)
Radiation · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

NCT05653856
View directory record Official record
Conditions
Metastasis From Malignant Tumor of Prostate (Disorder)
Interventions
64Cu-PSMA I&T
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
9
States / cities
New Haven, Connecticut • Hines, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Jul 22, 2026, 4:05 PM EDT
Withdrawn Phase 2 Interventional

Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer

NCT01409473
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate SBRT with concurrent boost to intraprostatic lesion(s)
Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Littleton, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 1Phase 2 Interventional

In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation

NCT00861107
View directory record Official record
Conditions
Metastatic Cancer
Interventions
AlloStim-7, percutaneous tumor cryoablation, AlloStim8 or AlloStim-9
Biological · Procedure
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Jul 22, 2026, 4:05 PM EDT
Recruiting Phase 1 Interventional

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

NCT07090148
View directory record Official record
Conditions
Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
Interventions
pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

NCT03081481
View directory record Official record
Conditions
Prostate Cancer
Interventions
PRX302
Drug
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
40 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Ocala, Florida • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jul 22, 2026, 4:05 PM EDT
Completed No phase listed Observational

Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions

NCT04867603
View directory record Official record
Conditions
Prostate Cancer
Interventions
[Ga-68]PSMA, PET/CT imaging
Drug · Device
Lead sponsor
Norbert Avril, M.D.
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Jul 22, 2026, 4:05 PM EDT
Active, not recruiting Phase 1 Interventional

Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)

NCT03269422
View directory record Official record
Conditions
Prostate Cancer
Interventions
MR-based image-guided, intensity-modulated radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 22, 2026, 4:05 PM EDT
Recruiting Phase 1 Interventional

Two Fraction Prostate SBRT With DIL SIB

NCT05864196
View directory record Official record
Conditions
Prostate Cancer
Interventions
Two-Fraction Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
2
States / cities
Mineola, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Completed No phase listed Observational

Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection and Evaluation of PSMA-PET for Diagnosis of Intraprostatic Lesions

NCT03213951
View directory record Official record
Conditions
Prostate Cancer
Interventions
Experimental beta probe, PSMA-PET
Other · Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Jul 22, 2026, 4:05 PM EDT
Completed Not applicable Interventional

PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy

NCT03635866
View directory record Official record
Conditions
Prostate Cancer
Interventions
Fluciclovine PET/MRI
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2020 · Synced Jul 22, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer

NCT04997018
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 22, 2026, 4:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

NCT05463796
View directory record Official record
Conditions
Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Interventions
Samples
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 22, 2026, 4:05 PM EDT